✦ LIBER ✦

In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: Does timing matter?

✍ Scribed by Susan C. Modesitt; Sarah J. Parsons

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

In vitro and in vivo histone deacetylase

✍ Amy L. Cooper; Victoria L. Greenberg; Pamela S. Lancaster; John R. van Nagell Jr 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 168 KB

The histone deacetylase inhibitor PXD101

✍ Young-Soon Na; Kyung-Ah Jung; Seung-Mi Kim; Yong Sang Hong; Min-Hee Ryu; Se Jin 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 874 KB

The histone deacetylase inhibitor PXD101

✍ Anthony Tumber; Laura S. Collins; Kamille Dumong Petersen; Annemette Thougaard; 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 420 KB

Phase 1 clinical trial of the novel prot

✍ Michael Millward, Timothy Price, Amanda Townsend, Christopher Sweeney, Andrew Sp 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 688 KB

Pre-clinical models of cellular therapy

✍ S. Ingersoll; S. Ahmad; G. Stoltzfus; M. Merchant; A. Ahmed; S. Patel; C. Edward 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 69 KB